Sympatholysis After Neuron-Specific, N-Type, Voltage-Sensitive Calcium Channel Blockade: First Demonstration of N-Channel Function in Humans

SNX-111 is the first neuronal N-type, voltagesensitive calcium channel (VSCC) blocker to enter clinical drug development. Areas of potential therapeutic utility include treatment of nociceptive and neuropathic pain and neuroprotection after ischemic brain injury. The data presented demonstrate that...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of cardiovascular pharmacology Vol. 30; no. 3; pp. 400 - 403
Main Authors:	McGuire, Dawn, Bowersox, Scott, Fellmann, Jere D, Luther, Robert R
Format:	Journal Article
Language:	English
Published:	Philadelphia, PA Lippincott-Raven Publishers 01-09-1997 Hagerstown, MD Lippincott
Subjects:	Adolescent Adult Analgesics Biological and medical sciences Blood Pressure - drug effects Calcium Channel Blockers - adverse effects Calcium Channel Blockers - pharmacology Cardiovascular system Heart Rate - drug effects Humans Hypotension, Orthostatic - chemically induced Injections, Intravenous Male Medical sciences Miscellaneous Neuropharmacology omega-Conotoxins Peptides - adverse effects Peptides - pharmacology Pharmacology. Drug treatments Human Calcium Calcium antagonist Electrophysiology Ionic channel Biological activity Neurophysiology Hypotensive drug Specificity Analgesic Sympatholytic Mechanism of action Subtype
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	SNX-111 is the first neuronal N-type, voltagesensitive calcium channel (VSCC) blocker to enter clinical drug development. Areas of potential therapeutic utility include treatment of nociceptive and neuropathic pain and neuroprotection after ischemic brain injury. The data presented demonstrate that SNX-111 is biologically active in humans and indicate for the first time a neurophysiologic function of N-type VSCCs in humans.
ISSN:	0160-2446 1533-4023
DOI:	10.1097/00005344-199709000-00019